An audit of prepectoral breast reconstructions using the Braxon® acellular dermal matrix (ADM).
Association of Breast Surgery ePoster Library. Bishop P. 05/13/19; 257106; P062
Paige Bishop
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
P062
Topic: Breast surgery
Background:An audit of the Braxon® method of prepectoral, single stage, direct-to-implant, breast reconstruction was performed by looking at infection rates and implant loss in the first 90 days post operatively. These measures are vital for patient safety and are key aspects of the recovery period.Method:A retrospective audit between June 2017-August 2018, where thirty-five Braxon reconstructions took place within one South London trust. Infection was defined as a patient needing IV antibiotics due to symptoms from the reconstructed breast between 7-90 days post operatively, or if there was microbiological data. Implant loss was if the implant needed removing. The audit was formally approved and presented within the Trust Clinical Governance framework. Results:Thirty-three reconstructions took place for cancer and three for risk reduction (Age range 28-65).In the 90-day period, infection/cellulitis had affected 6 (17%). Of these patients, half were previous or current smokers, and none had previously undergone radiotherapy. Two patients were affected by implant loss (5.7%). One due to nipple necrosis with wound dehiscence, the other due to infection. Both patients were aged over 50 and either a present or past smoker. The national figure for implant loss is similar at 6.9%. Conclusions:The Braxon ADM method of reconstruction appears to be safe in relation to implant loss and infection rates, with this data being comparable to national data. The results emphasise the need for good patient selection. This centre is an active participant in the National Audit of immediate breast reconstructions (iBRA).
Topic: Breast surgery
Background:An audit of the Braxon® method of prepectoral, single stage, direct-to-implant, breast reconstruction was performed by looking at infection rates and implant loss in the first 90 days post operatively. These measures are vital for patient safety and are key aspects of the recovery period.Method:A retrospective audit between June 2017-August 2018, where thirty-five Braxon reconstructions took place within one South London trust. Infection was defined as a patient needing IV antibiotics due to symptoms from the reconstructed breast between 7-90 days post operatively, or if there was microbiological data. Implant loss was if the implant needed removing. The audit was formally approved and presented within the Trust Clinical Governance framework. Results:Thirty-three reconstructions took place for cancer and three for risk reduction (Age range 28-65).In the 90-day period, infection/cellulitis had affected 6 (17%). Of these patients, half were previous or current smokers, and none had previously undergone radiotherapy. Two patients were affected by implant loss (5.7%). One due to nipple necrosis with wound dehiscence, the other due to infection. Both patients were aged over 50 and either a present or past smoker. The national figure for implant loss is similar at 6.9%. Conclusions:The Braxon ADM method of reconstruction appears to be safe in relation to implant loss and infection rates, with this data being comparable to national data. The results emphasise the need for good patient selection. This centre is an active participant in the National Audit of immediate breast reconstructions (iBRA).
P062
Topic: Breast surgery
Background:An audit of the Braxon® method of prepectoral, single stage, direct-to-implant, breast reconstruction was performed by looking at infection rates and implant loss in the first 90 days post operatively. These measures are vital for patient safety and are key aspects of the recovery period.Method:A retrospective audit between June 2017-August 2018, where thirty-five Braxon reconstructions took place within one South London trust. Infection was defined as a patient needing IV antibiotics due to symptoms from the reconstructed breast between 7-90 days post operatively, or if there was microbiological data. Implant loss was if the implant needed removing. The audit was formally approved and presented within the Trust Clinical Governance framework. Results:Thirty-three reconstructions took place for cancer and three for risk reduction (Age range 28-65).In the 90-day period, infection/cellulitis had affected 6 (17%). Of these patients, half were previous or current smokers, and none had previously undergone radiotherapy. Two patients were affected by implant loss (5.7%). One due to nipple necrosis with wound dehiscence, the other due to infection. Both patients were aged over 50 and either a present or past smoker. The national figure for implant loss is similar at 6.9%. Conclusions:The Braxon ADM method of reconstruction appears to be safe in relation to implant loss and infection rates, with this data being comparable to national data. The results emphasise the need for good patient selection. This centre is an active participant in the National Audit of immediate breast reconstructions (iBRA).
Topic: Breast surgery
Background:An audit of the Braxon® method of prepectoral, single stage, direct-to-implant, breast reconstruction was performed by looking at infection rates and implant loss in the first 90 days post operatively. These measures are vital for patient safety and are key aspects of the recovery period.Method:A retrospective audit between June 2017-August 2018, where thirty-five Braxon reconstructions took place within one South London trust. Infection was defined as a patient needing IV antibiotics due to symptoms from the reconstructed breast between 7-90 days post operatively, or if there was microbiological data. Implant loss was if the implant needed removing. The audit was formally approved and presented within the Trust Clinical Governance framework. Results:Thirty-three reconstructions took place for cancer and three for risk reduction (Age range 28-65).In the 90-day period, infection/cellulitis had affected 6 (17%). Of these patients, half were previous or current smokers, and none had previously undergone radiotherapy. Two patients were affected by implant loss (5.7%). One due to nipple necrosis with wound dehiscence, the other due to infection. Both patients were aged over 50 and either a present or past smoker. The national figure for implant loss is similar at 6.9%. Conclusions:The Braxon ADM method of reconstruction appears to be safe in relation to implant loss and infection rates, with this data being comparable to national data. The results emphasise the need for good patient selection. This centre is an active participant in the National Audit of immediate breast reconstructions (iBRA).
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}